Development and Characterization of Innovative Nifurtimox Formulations as Therapeutic Alternative for Chagas Disease.

ABSTRACT: Chagas disease, caused by Trypanosoma cruzi, remains a neglected tropical disease with limited and often suboptimal chemotherapeutic treatment options. The WHO recommends nifurtimox (NFX) for treating Chagas disease, which, although it is effective in the early stages of infection, has variable efficacy in the chronic phase and induces adverse effects that frequently compromise the continuity of the treatment. This study focused on the development and characterization of innovative lipid-based self-emulsifying drug delivery systems (SEDDSs) and poly(ε-caprolactone) implants containing NFX. The SEDDS formulations modified the NFX release extent and rate. The implant characterization included thermal analysis, X-ray diffraction, thermo-optical analysis, and scanning electron microscop

SUBMITTER: Mazzeti AL 

PROVIDER: S-EPMC11860281 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature